Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06831643

Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure

Acute liver failure is a multisystem disorder characterized by a syndrome of jaundice, coagulopathy, and encephalopathy with high mortality in the absence of liver transplantation. The pathogenesis of multiorgan failure (MOF) in ALF has been attributed to the release of damage-associated molecular patterns (DAMPs) from injured hepatic cells and microbial pathogen-associated molecular patterns (PAMPs) in the presence of superimposed infection or bacterial translocation.The innate immune cells activated by PAMPs and DAMPs produce pro-inflammatory cytokines [interleukin (IL)-6, IL-1b, IL-8, tumor necrosis factor-alpha (TNF-a)]. Studies indicate that the removal of inflammatory mediators appears to play a role in the treatment of ALF and are removed by some apheresis techniques. Hence therapeutic exchange (TPE) has been used as adjunct or standalone therapy for bridging patients to recovery or LT. TPE to treat liver failure involves two steps-removal of plasma from a patient with liver failure and replacing this with equal volume of fluid; in view of the coagulopathy seen in liver failure patients, the preferred fluid for replacement is fresh frozen plasma. Different doses of PLEX have been used to treat liver failure patients with high, standard or low volume PLEX, to treat ALF. Presently American Apheresis Society guidelines consider High Volume TPE (HV-TPE) as first line the management of ALF. But HV-TPE, apart from strain on blood bank resources (large volumes of fresh frozen plasma needed), also carries risk of transfusion associated acute lung complications, risk of blood borne virus infection, and so on make the use of low-volume PLEX attractive compared to high-volume PLEX. Hence this study is being carried out to consider the safety and efficacy of standard volume plasma exchange (SV-TPE) vs. HV-TPE in Pediatric ALF.

Recruiting

Interested in participating?

Request Info

Key information

Age range

3 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institute of Liver & Biliary Sciences

New Delhi, National Capital Territory of Delhi, 110070, India

Location status: Recruiting

Location contact

Dr Ashray S Patel, MD

CONTACT

[email protected]

01146300000

About this study

Aim: To study the efficacy in terms of the native liver survival, of standard volume plasma exchange as compared to high volume plasma exchange in Pediatric ALF.

Study Design: Open label pilot Randomized Control trial. Sample size: Time bound. All cases presenting during the study period will be included in the study.

Standard Medical Therapy:

  • All patients are were managed by a multidisciplinary team at Live Coma ICU.
  • Intubation and ventilation were undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema
  • Ventilation was managed by fentanyl and propofol along with the use of atracurium for paralysis wherever required.
  • Hemodynamics, ONSD and TCD are monitored routinely.
  • All patients received N-acetylcysteine.
  • Neuro-protective measures such as hypertonic saline, head end elevation, minimal stimulation, propofol and thiopentone infusion are followed as per protocol.
  • Anti-ammonia measures like sodium benzoate, CRRT as well started as per protocol.
  • CRRT is done for routine renal indications, hyperlactetmia, hyperammonemia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 3 years to 18 years
  • Fulfilling PALFSG definition (J Pediatr. 2006 May;148(5):652-658).
  • Baseline INR ≥ 2.5, and increasing INR (any value) and/or worsening hepatic. encephalopathy (> 1 grade change) after 6 to 12 hours of standard medical therapy.

Exclusion criteria

  • Disseminated intravascular coagulation
  • Marked hemodynamic instability requiring a high dose of vasopressors (norepinephrine >0.5 mcg/kg/min)
  • Signs of irreversible brain injury
  • Any severe cardio-pulmonary pre-existing disease
  • Septic Shock

Treatment and study plan

Standard Medical Treatment

Drug

Standard Medical treatment

Therapeutic Plasma Excahnge

Biological

Therapeutic Plasma Excahnge

Primary outcomes

  1. Native liver survival at day 21, in patients receiving standard volume (1.3-1.5 times plasma volume) therapeutic plasma exchange and those receiving high volume (2-2.2 times plasma volume) therapeutic plasma exchange in children with acute.

    Time frame: Day 21

Secondary outcomes

  1. Clinical parameters:Grades of Hepatic Encephalopathy from day 0 to day 4.

    Time frame: Day 0,Day1,Day2,day3,Day 4

  2. Clinical parameters: Optic Nerve Sheet Diameter (Left/Right) from day 0 to day 4.

    Time frame: Day 0,Day1,Day2,day3,Day 4

  3. Clinical parameters: Mean arterial pressure from day 0 to day 4.

    Time frame: Day 0,Day1,Day2,day3,Day 4

  4. Proportion of patients with change in Liver Function test from day 0 to day 4.

    Time frame: Day 0,Day1,Day2,day3,Day 4

  5. Biochemical parameters: International normalized ratio from day 0 to day 4.

    Time frame: Day 0,Day1,Day2,day3,Day 4

  6. Biochemical parameters:Arterial ammonia from day 0 to day 4.

    Time frame: Day 0,Day1,Day2,day3,Day 4

  7. Biochemical parameters: Arterial lactate from day 0 to day 4.

    Time frame: Day 0,Day1,Day2,day3,Day 4

  8. Patient with change in Cytokines level at day 0 and day 3.

    Time frame: Day 0 & Day 3

  9. Impact on other factors at day 0 and 3: Growth Factors (G-CSF).

    Time frame: Day 0 & Day 3

  10. Impact on other factors at day 0 and 3: Damage Associated Molecular Pattern (DAMPS) (S100B, HMGB1).

    Time frame: Day 0 & Day 3

  11. Impact on other factors at day 0 and 3: Von Willebrand Factor.

    Time frame: Day 0 & Day 3

  12. Adverse effects in both groups

    Time frame: Within Day 21

  13. Duration of mechanical ventilation & ICU stay.

    Time frame: Within Day 21

  14. Mortality

    Time frame: Within Day 21

  15. Number of participants with Liver Transplant

    Time frame: Within Day 21

Study contacts

Contact information is provided by the study sponsor or research team.

Dr Ashray S Patel, MD

CONTACT

[email protected]

01146300000

Dr Vikrant Sood, DM

CONTACT

[email protected]

01146300000

Sponsors and collaborators

Lead sponsor

Institute of Liver and Biliary Sciences, India

Other

Registry information

Official study title

Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure - A Pilot Randomized Control Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 18, 2025
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.